Akebia Therapeutics (AKBA) EBT (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of EBT data on file, last reported at -$8.9 million in Q1 2026.

• On a quarterly basis, EBT fell 246.07% year-over-year to -$8.9 million in Q1 2026; TTM through Mar 2026 was -$18.8 million, a 58.6% increase from a year earlier, with the FY2025 full-year figure at -$3.7 million, up 94.64% from the prior year.
• EBT for Q1 2026 stood at -$8.9 million, up from -$11.2 million in the prior quarter.
• Over the last five years, EBT for AKBA reached as high as $31.4 million in Q2 2022 and fell as low as -$62.3 million in Q1 2022.
• Historically, EBT has averaged -$13.0 million across 5 years, with a median of -$11.2 million in 2023.
• Across the five-year window, EBT soared 138.24% in 2022 and sank 3814.01% in 2024, its largest moves.
• Year by year, EBT stood at -$4.1 million in 2022, then surged by 114.89% to $614000.0 in 2023, then sank by 3814.01% to -$22.8 million in 2024, then surged by 50.73% to -$11.2 million in 2025, then increased by 20.53% to -$8.9 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$8.9 million in Q1 2026, -$11.2 million in Q4 2025, and $1.2 million in Q3 2025.